Relmada Therapeutics (RLMD) Receives U.S. Patent Related to REL-1017
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Relmada Therapeutics, Inc. (OTC: RLMD) announced that the U.S. Patent and Trademark Office has issued U.S. Patent 9,468,611 for "d-Methadone for the Treatment of Psychiatric Symptoms." The patent contains claims that provide broad coverage for d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist, as a treatment for psychological and psychiatric disorders, comprising depression, anxiety, fatigue, and mood instability including pseudo-bulbar affect (PBA) for which there is currently only one U.S. Food and Drug Administration (FDA) approved treatment.
"The issuance of this key patent, which covers our lead product candidate REL-1017, further expands our intellectual property position," said Sergio Traversa, CEO of Relmada Therapeutics. "We look forward to initiating a Phase II proof-of-concept study with REL-1017 as a rapidly acting depression treatment as soon as feasible."
In May 2016, Relmada reported positive results from an in vivo study to determine whether REL-1017 elicits antidepressant-like effects within 24 hours after a single administration based on results of the forced swim test, a well-validated animal model to predict antidepressant effects. At all doses tested, REL-1017 significantly decreased immobility of rats compared to the vehicle, suggesting antidepressant-like activity. In addition, the effect of REL-1017 on immobility at the two highest doses tested was larger than the effect seen with ketamine, a noncompetitive NMDA receptor antagonist that has been thoroughly characterized in this model and has demonstrated rapid onset of activity in several clinical studies targeting treatment of depression, but has also been shown in multiple studies to present a high risk of toxicity.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PICO Holdings (PICO) Announces Leadership, Governance Changes; Terminates Central Square Agreement
- Johnson & Johnson (JNJ) Receives Adverse Decision in Texas Hip Implants Case; Will Pay $1B
- Sears Holdings (SHLD) Director Mnuchin Resigns Amid Trump Nod
Create E-mail Alert Related CategoriesCorporate News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!